French Lack Confidence in Macron Virus Effort, Poll Shows
(Bloomberg) -- A majority of French people lack confidence in the government's ability to deal effectively with the coronavirus pandemic or manage the vaccination campaign, even after President Emmanuel Macron accelerated efforts to distribute the shots, according to a survey in newspaper Journal du Dimanche.
The percentage of those lacking confidence in the management of the crisis stood at 62%, according to the survey by Ifop for the newspaper, little changed from readings earlier this month and in December. The poll of 1,028 people conducted Thursday and Friday found that 63% doubted the handling of the inoculation effort.
Macron and Prime Minister Jean Castex have come under criticism for the slow start to vaccinations since they began Dec. 27. Government officials vowed to speed up the process and said Saturday that 100,000 people will have been vaccinated by the end of the weekend.
“We want to go quickly; we wanted first to do things safely, and to be serious,” Castex said Saturday in televised remarks to reporters during a visit to a vaccination center in Tarbes, southwest France.
France reported 20,177 new coronavirus cases on Saturday, while the number of deaths increased by 171 to 67,599, according to statistics from the national health agency. While the government has been aiming to bring the number of daily new cases to below 5,000, there has been around four times that number on most days in January, prompting officials to put more of the nation under an earlier curfew.
The virus is circulating at an elevated level, with an average of 18,000 new cases daily, Health Minister Olivier Veran said Sunday in an interview with Cnews television and Europe1 radio.
Asked whether France will have to resort to a nationwide lockdown for the third time since the outbreak began, he said that case numbers are still growing slowly, unlike in other European countries such as the U.K. and Germany.
“If we find that there's again a strong growth in the epidemic, with pressure on the health system, obviously that will have consequences for the decisions we make,” he said. “We've always taken and will continue to take the steps necessary, at the moment when it's necessary to take them, to protect the health of the French.”
©2021 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.